Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Momenta Pharmaceuticals, Inc. Snapshot | 6 | 1 |
| Momenta Pharmaceuticals, Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Momenta Pharmaceuticals, Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Momenta Pharmaceuticals, Inc. Pipeline Review | 10 | 2 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Momenta Pharmaceuticals, Inc. Pipeline Products Glance | 12 | 5 |
| Momenta Pharmaceuticals, Inc. Late Stage Pipeline Products | 12 | 1 |
| Phase III Products/Combination Treatment Modalities | 12 | 1 |
| Momenta Pharmaceuticals, Inc. Clinical Stage Pipeline Products | 13 | 1 |
| Phase II Products/Combination Treatment Modalities | 13 | 1 |
| Phase I Products/Combination Treatment Modalities | 14 | 1 |
| Momenta Pharmaceuticals, Inc. Early Stage Pipeline Products | 15 | 1 |
| Preclinical Products/Combination Treatment Modalities | 15 | 1 |
| Discovery Products/Combination Treatment Modalities | 16 | 1 |
| Momenta Pharmaceuticals, Inc. Drug Profiles | 17 | 13 |
| adalimumab biosimilar | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 1 |
| necuparanib | 18 | 1 |
| Product Description | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| R&D Progress | 18 | 2 |
| M-281 | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| abatacept biosimilar | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 1 |
| Antibody for Autoimmune Disorders and Inflammation | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| M-230 | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| M-615 | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| M-706 | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| M-710 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| M-730 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| M-740 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| Monoclonal Antibodies for Autoimmune Diseases | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| Momenta Pharmaceuticals, Inc. Pipeline Analysis | 30 | 4 |
| Momenta Pharmaceuticals, Inc. Pipeline Products by Target | 30 | 1 |
| Momenta Pharmaceuticals, Inc. Pipeline Products by Route of Administration | 31 | 1 |
| Momenta Pharmaceuticals, Inc. Pipeline Products by Molecule Type | 32 | 1 |
| Momenta Pharmaceuticals, Inc. Pipeline Products by Mechanism of Action | 33 | 1 |
| Momenta Pharmaceuticals, Inc. Recent Pipeline Updates | 34 | 5 |
| Momenta Pharmaceuticals, Inc. Dormant Projects | 39 | 1 |
| Momenta Pharmaceuticals, Inc. Discontinued Pipeline Products | 40 | 1 |
| Discontinued Pipeline Product Profiles | 40 | 1 |
| bevacizumab biosimilar | 40 | 1 |
| Momenta Pharmaceuticals, Inc. Company Statement | 41 | 2 |
| Momenta Pharmaceuticals, Inc. Locations And Subsidiaries | 43 | 1 |
| Head Office | 43 | 1 |
| Other Locations &Subsidiaries | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |